Clinical Trial Update: Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations [Phase 1]

View source ↗

Summary

A Phase 1 single-dose crossover study comparing two EMB-001 formulations to assess bioavailability and the effect of food in Cocaine Use Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cocaine Use Disorder

Drugs mentioned

• EMB-001 (Metyrapone/Oxazepam combination)

Snippet

Sponsor: Embera NeuroTherapeutics, Inc. | Conditions: Cocaine Use Disorder | Phase 1 | Status: COMPLETED